State of Alaska Department of Revenue’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $610K | Sell |
7,375
-2,949
| -29% | -$237K | 0.01% | 1321 |
|
|
2026
Q1 | $793K | Sell |
10,324
-198
| -2% | -$15.5K | 0.01% | 1191 |
|
|
2025
Q4 | $830K | Buy |
10,522
+565
| +6% | +$48.9K | 0.01% | 1183 |
|
|
2025
Q3 | $911K | Sell |
9,957
-159
| -2% | -$13K | 0.01% | 1127 |
|
|
2025
Q2 | $659K | Buy |
10,116
+920
| +10% | +$59.9K | 0.01% | 1252 |
|
|
2025
Q1 | $615K | Sell |
9,196
-216
| -2% | -$12.9K | 0.01% | 1269 |
|
|
2024
Q4 | $520K | Sell |
9,412
-55
| -0.6% | -$3.16K | 0.01% | 1371 |
|
|
2024
Q3 | $564K | Buy |
9,467
+464
| +5% | +$28.3K | 0.01% | 1366 |
|
|
2024
Q2 | $573K | Sell |
9,003
-181
| -2% | -$11.8K | 0.01% | 1307 |
|
|
2024
Q1 | $634K | Sell |
9,184
-744
| -7% | -$44.9K | 0.01% | 1265 |
|
|
2023
Q4 | $547K | Sell |
9,928
-47
| -0.5% | -$2.59K | 0.01% | 1320 |
|
|
2023
Q3 | $579K | Buy |
9,975
+813
| +9% | +$46.9K | 0.01% | 1249 |
|
|
2023
Q2 | $493K | Buy |
9,162
+796
| +10% | +$35.3K | 0.01% | 1370 |
|
|
2023
Q1 | $332K | Sell |
8,366
-141
| -2% | -$5.95K | ﹤0.01% | 1512 |
|
|
2022
Q4 | $342K | Buy |
8,507
+148
| +2% | +$5.56K | ﹤0.01% | 1504 |
|
|
2022
Q3 | $268K | Sell |
8,359
-807
| -9% | -$27.6K | ﹤0.01% | 1543 |
|
|
2022
Q2 | $271K | Buy |
9,166
+320
| +4% | +$9.23K | ﹤0.01% | 1551 |
|
|
2022
Q1 | $248K | Buy |
8,846
+1,180
| +15% | +$44K | ﹤0.01% | 1566 |
|
|
2021
Q4 | $353K | Buy |
7,666
+475
| +7% | +$20.4K | ﹤0.01% | 1563 |
|
|
2021
Q3 | $236K | Buy |
7,191
+322
| +5% | +$10K | ﹤0.01% | 1605 |
|
|
2021
Q2 | $240K | Buy |
6,869
+350
| +5% | +$11.9K | ﹤0.01% | 1596 |
|
|
2021
Q1 | $235K | Sell |
6,519
-970
| -13% | -$30.4K | ﹤0.01% | 1587 |
|
|
2020
Q4 | $217K | Sell |
7,489
-1,463
| -16% | -$41.9K | ﹤0.01% | 1576 |
|
|
2020
Q3 | $252K | Buy |
8,952
+230
| +3% | +$6.85K | ﹤0.01% | 1481 |
|
|
2020
Q2 | $282K | Buy |
8,722
+100
| +1% | +$3.59K | ﹤0.01% | 1462 |
|
|
2020
Q1 | $351K | Buy |
8,622
+1,600
| +23% | +$85.1K | 0.01% | 1252 |
|
|
2019
Q4 | $433K | Sell |
7,022
-116
| -2% | -$7.68K | 0.01% | 1368 |
|
|
2019
Q3 | $520K | Buy |
7,138
+4,277
| +149% | +$320K | 0.01% | 1257 |
|
|
2019
Q2 | $235K | Buy |
2,861
+67
| +2% | +$4.76K | ﹤0.01% | 1407 |
|
|
2019
Q1 | $197K | Buy |
2,794
+35
| +1% | +$2.06K | ﹤0.01% | 1460 |
|
|
2018
Q4 | $124K | Sell |
2,759
-210
| -7% | -$11K | ﹤0.01% | 1537 |
|
|
2018
Q3 | $167K | Hold |
2,969
| – | – | ﹤0.01% | 1541 |
|
|
2018
Q2 | $198K | Buy |
2,969
+90
| +3% | +$5.62K | ﹤0.01% | 1487 |
|
|
2018
Q1 | $167K | Buy |
2,879
+1,100
| +62% | +$69.8K | ﹤0.01% | 1463 |
|
|
2017
Q4 | $114K | Hold |
1,779
| – | – | ﹤0.01% | 1481 |
|
|
2017
Q3 | $93K | Buy |
1,779
+190
| +12% | +$9.06K | ﹤0.01% | 1196 |
|
|
2017
Q2 | $74K | Buy |
1,589
+709
| +81% | +$34.2K | 0.01% | 1158 |
|
|
2017
Q1 | $43K | Buy |
880
+20
| +2% | +$1.12K | ﹤0.01% | 1139 |
|
|
2016
Q4 | $52K | Buy |
+860
| New | +$52.6K | 0.01% | 829 |
|
Other funds holding ANIP
SCM
N
State of Alaska Department of Revenue's ANIP Position: Q2 2026 in Review
State of Alaska Department of Revenue reduced its ANI Pharmaceuticals (ANIP) stake by 29% in Q2 2026, selling an estimated $237K and leaving 7,375 shares worth $610K. The position accounts for 0.01% of the portfolio, ranked #1321.
State of Alaska Department of Revenue first reported a position in ANIP in Q4 2016 and has held it in 39 quarters since. The position peaked at $911K in Q3 2025. 177 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- State of Alaska Department of Revenue held 7,375 shares of ANI Pharmaceuticals worth $610K as of Q2 2026.
- State of Alaska Department of Revenue sold 2,949 ANI Pharmaceuticals shares in Q2 2026, an estimated $237K.
- ANI Pharmaceuticals made up 0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #1321 holding.
- State of Alaska Department of Revenue first reported a position in ANI Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- State of Alaska Department of Revenue's ANI Pharmaceuticals position peaked at $911K in Q3 2025.
- 177 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.